December 2008 Oncology News International

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

William R. Kennedy, MD

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Tim Cortese

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.

Russ Conroy

NOTCH1 Mutational Status May Predict ICI Outcomes in Esophageal Cancer

Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.

According to comparative single-cell transcriptome analyses, NOTCH1 deficiency facilitated a more immunologically active microenvironment in ESCC tumors.

Same-Day G-CSF After Chemo Appears Safe, Efficacious in Breast Cancer

According to comparative single-cell transcriptome analyses, NOTCH1 deficiency facilitated a more immunologically active microenvironment in ESCC tumors.

Related Content

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

William R. Kennedy, MD

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Tim Cortese

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Russ Conroy

NOTCH1 Mutational Status May Predict ICI Outcomes in Esophageal Cancer

Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.